找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: HCV: The Journey from Discovery to a Cure; Volume I Michael J. Sofia Book 2019 Springer Nature Switzerland AG 2019 HCV genome.Molecular Vir

[复制链接]
查看: 32702|回复: 56
发表于 2025-3-21 16:49:19 | 显示全部楼层 |阅读模式
书目名称HCV: The Journey from Discovery to a Cure
副标题Volume I
编辑Michael J. Sofia
视频video
概述Provides a comprehensive compilation of discoveries that led to the cure for HCV by the leading researchers in the field.Traces all aspects of HCV research that contributed to the development of key d
丛书名称Topics in Medicinal Chemistry
图书封面Titlebook: HCV: The Journey from Discovery to a Cure; Volume I Michael J. Sofia Book 2019 Springer Nature Switzerland AG 2019 HCV genome.Molecular Vir
描述Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide..This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is t
出版日期Book 2019
关键词HCV genome; Molecular Virology; HCV replicon system; IFN therapy; Polymerase Inhibitors; Sofosbuvir; Becla
版次1
doihttps://doi.org/10.1007/978-3-030-28207-3
isbn_softcover978-3-030-28209-7
isbn_ebook978-3-030-28207-3Series ISSN 1862-2461 Series E-ISSN 1862-247X
issn_series 1862-2461
copyrightSpringer Nature Switzerland AG 2019
The information of publication is updating

书目名称HCV: The Journey from Discovery to a Cure影响因子(影响力)




书目名称HCV: The Journey from Discovery to a Cure影响因子(影响力)学科排名




书目名称HCV: The Journey from Discovery to a Cure网络公开度




书目名称HCV: The Journey from Discovery to a Cure网络公开度学科排名




书目名称HCV: The Journey from Discovery to a Cure被引频次




书目名称HCV: The Journey from Discovery to a Cure被引频次学科排名




书目名称HCV: The Journey from Discovery to a Cure年度引用




书目名称HCV: The Journey from Discovery to a Cure年度引用学科排名




书目名称HCV: The Journey from Discovery to a Cure读者反馈




书目名称HCV: The Journey from Discovery to a Cure读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-22 00:19:25 | 显示全部楼层
发表于 2025-3-22 01:00:21 | 显示全部楼层
发表于 2025-3-22 04:50:50 | 显示全部楼层
https://doi.org/10.1057/9781137339096hepatocellular carcinoma. The HCV genome was cloned molecularly in 1989, and around 25 years later, antiviral therapy has been established that eliminates the virus in more than 95% of infected individuals. To reach this goal, several hurdles had to be overcome, a major one having been the developme
发表于 2025-3-22 11:04:48 | 显示全部楼层
发表于 2025-3-22 15:27:02 | 显示全部楼层
发表于 2025-3-22 18:53:12 | 显示全部楼层
The Chinese Path Toward a Leaner Governmenteffort on the discovery and development of interferon (IFN)-free therapies that are well tolerated and have increased cure rates. This chapter describes the discovery and development of sofosbuvir, the first live-targeting prodrug of a nucleotide analog, and contains a detailed overview of the synth
发表于 2025-3-23 00:01:24 | 显示全部楼层
A Modified Vision of Divine Determination, The history of the discovery and optimization of leads acting at each of these sites is discussed. The many clinical candidates that emerged from these efforts are described, together with their impact on emerging regimens of increasing effectiveness.
发表于 2025-3-23 05:26:21 | 显示全部楼层
HJD-04: The Chinese-Developed Systemass of indolobenzazepines. Within this research, a strategic decision to abandon a highly potent but physiochemically problematic series in favor of one of lower molecular weight and potency was key in the realization of the program’s objectives. Subsequent cycles of analog design incorporating prog
发表于 2025-3-23 07:13:18 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-11 09:04
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表